• J. Clin. Oncol. · Dec 2015

    Randomized Controlled Trial Multicenter Study

    Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

    • Thierry André, Armand de Gramont, Dewi Vernerey, Benoist Chibaudel, Franck Bonnetain, Annemilaï Tijeras-Raballand, Aurelie Scriva, Tamas Hickish, Josep Tabernero, Jean Luc Van Laethem, Maria Banzi, Eduard Maartense, Einat Shmueli, Goran U Carlsson, Werner Scheithauer, Demetris Papamichael, Marcus Möehler, Stefania Landolfi, Pieter Demetter, Soudhir Colote, Christophe Tournigand, Christophe Louvet, Alex Duval, Jean-François Fléjou, and Aimery de Gramont.
    • Thierry André and Jean-François Fléjou, Hôpital St Antoine; Thierry André and Jean-François Fléjou, University Pierre et Marie Curie Paris VI; Thierry André, Benoist Chibaudel, Annemilaï Tijeras-Raballand, Soudhir Colote, and Aimery de Gramont, Groupe Coopérateur Multdisciplinaire en Ocologie (GERCOR) Oncology Multidisciplinary Group and GERCOR-Innovative Research Consortium; Christophe Louvet, Institut Mutualiste Montsouris; Alex Duval, L'Institut National de la Santé et de la Recherche Médicale UMRS 938, Paris; Armand de Gramont, Benoist Chibaudel, Annemilaï, Tijeras Raballand, Aurelie Scriva, and Aimery de Gramont, Institut Hospitalier Franco Britannique, Levallois-Perret; Dewi Vernerey and Franck Bonnetain, Hôpital Saint-Jacques, Besançon; Christophe Tournigand, Hôpital Henri Mondor, Créteil, France; Armand de Gramont, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Tamas Hickish, Dorset Bournemouth University, Dorset, United Kingdom; Josep Tabernero and Stefania Landolfi, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona; Josep Tabernero, TTD Group, Madrid, Spain; Jean Luc Van Laethem and Pieter Demetter, Hôpital Universitaire Erasme, Brussels, Belgium; Maria Banzi, Arcispedale Santa Maria Nuova, Reggio, Italy; Eduard Maartense, Reinier de Graaf Groep, Delft, the Netherlands; Einat Shmueli, Sheba Medical Center, Tel Hashomer, Israel; Goran U. Carlsson, Sahlgrenska University Hospital, Östra, Sweden; Werner Scheithauer, Medical University of Vienna, Vienna, Austria; Demetris Papamichael, B.O. Cyprus Oncology Centre, Nicosia, Cyprus; and Marcus Möehler, University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany. thierry.andre@aphp.fr.
    • J. Clin. Oncol. 2015 Dec 10; 33 (35): 4176-87.

    PurposeThe MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation.MethodsSurvival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens.ResultsAfter a median follow-up of 9.5 years, 10-year OS rates in the bolus/infusional fluorouracil plus leucovorin (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX4) arms were 67.1% versus 71.7% (hazard ratio [HR], 0.85; P = .043) in the whole population, 79.5% versus 78.4% for stage II (HR, 1.00; P = .980), and 59.0% versus 67.1% for stage III (HR, 0.80; P = .016) disease. Ninety-five patients (9.4%) had MMR-deficient (dMMR) tumors, and 94 (10.4%) had BRAF mutation. BRAF mutation was not prognostic for OS (P = .965), but dMMR was an independent prognostic factor (HR, 2.02; 95% CI, 1.15 to 3.55; P = .014). HRs for DFS and OS benefit in the FOLFOX4 arm were 0.48 (95% CI, 0.20 to 1.12) and 0.41 (95% CI, 0.16 to 1.07), respectively, in patients with stage II to III dMMR and 0.50 (95% CI, 0.25 to 1.00) and 0.66 (95% CI, 0.31 to 1.42), respectively, in those with BRAF mutation.ConclusionThe OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the disease severity, was confirmed at 10 years in patients with stage II to III colon cancer. These updated results support the use of FOLFOX in patients with stage III disease, including those with dMMR or BRAF mutation.© 2015 by American Society of Clinical Oncology.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…